Halozyme Therapeutics, Inc.
HALO
$64.66
-$1.88-2.83%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 354.26M | 325.72M | 264.86M | 298.01M | 290.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 354.26M | 325.72M | 264.86M | 298.01M | 290.08M |
| Cost of Revenue | 72.49M | 46.36M | 51.63M | 62.50M | 67.88M |
| Gross Profit | 281.77M | 279.36M | 213.23M | 235.51M | 222.20M |
| SG&A Expenses | 46.09M | 41.61M | 42.36M | 42.25M | 41.24M |
| Depreciation & Amortization | 17.76M | 17.76M | 17.76M | 17.76M | 17.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.34M | 123.28M | 123.33M | 122.51M | 126.89M |
| Operating Income | 217.92M | 202.44M | 141.54M | 175.50M | 163.20M |
| Income Before Tax | 218.96M | 204.94M | 143.83M | 178.21M | 165.15M |
| Income Tax Expenses | 43.73M | 39.78M | 25.73M | 41.20M | 28.14M |
| Earnings from Continuing Operations | 175.23M | 165.16M | 118.10M | 137.01M | 137.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 175.23M | 165.16M | 118.10M | 137.01M | 137.01M |
| EBIT | 217.92M | 202.44M | 141.54M | 175.50M | 163.20M |
| EBITDA | 236.84M | 221.44M | 160.48M | 194.52M | 182.16M |
| EPS Basic | 1.49 | 1.36 | 0.96 | 1.08 | 1.08 |
| Normalized Basic EPS | 1.17 | 1.06 | 0.72 | 0.87 | 0.81 |
| EPS Diluted | 1.43 | 1.33 | 0.93 | 1.06 | 1.05 |
| Normalized Diluted EPS | 1.12 | 1.03 | 0.70 | 0.85 | 0.79 |
| Average Basic Shares Outstanding | 117.22M | 121.34M | 123.22M | 126.41M | 126.85M |
| Average Diluted Shares Outstanding | 122.33M | 124.16M | 126.64M | 128.98M | 130.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |